NEW
Jul 10, 2026 • Press Release
•
28-program biologics pipeline opens to licensing
91.4% Program Success
Across 58 Antibody
Affinity Maturation Campaigns
Ainnocence reports performance from 75 completed protein design programs and opens 28 antibody, bispecific and ADC programs to licensing across oncology, immunology and metabolic indications.
Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20–50 samples per round.
91.4%
Affinity Maturation Success
(53 of 58 campaigns)
53%
De Novo Hits on Novel Targets
(9 of 17, no structure)
28
Sub-nM Programs
7 reached ≤ 100 pM
28
Programs to License
of 37 in pipeline
Picomolar Leads Across Formats — 28 sub-nM programs, 7 at ≤100 pM
| Target / Program | Format | KD |
|---|---|---|
| IL-15 × IL-21 | Bispecific | ~0.09 pM |
| Anti-C1q | mAb | 1–20 pM |
| TNFα – OX40L | Bispecific | 8.6 pM |
| TL1A × p40 | Bispecific | 23 pM |
| Anti-VEGF | scFv-IgG | 27.8–34.6 pM |
| Anti-IL-36R | Fab | < 1 pM* |
| Anti-TROP2 | ADC | 0.37–0.43 nM |
| Anti-B7-H3 | ADC-enabling | ~0.56 nM |
*Below assay detection limit (1 pM) for 13 of 21 matured variants.
